Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial

医学 扎那米韦 奥司他韦 临床终点 临床试验 神经氨酸酶抑制剂 人口 内科学 随机对照试验 儿科 外科 2019年冠状病毒病(COVID-19) 传染病(医学专业) 疾病 环境卫生
作者
Francisco M. Marty,Joan Vidal-Puigserver,Carol L. Clark,Sandeep K. Gupta,Esperanza Merino,Denis Garot,Marianne J. Chapman,Frédérique Jacobs,Eduardo Rodríguez-Noriega,Petr Husa,Denise Shortino,Helen Watson,Phillip J. Yates,Amanda Peppercorn
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:5 (2): 135-146 被引量:102
标识
DOI:10.1016/s2213-2600(16)30435-0
摘要

Neuraminidase inhibitors are effective for the treatment of acute uncomplicated influenza. However, there is an unmet need for intravenous treatment for patients admitted to hospital with severe influenza. We studied whether intravenous zanamivir was a suitable treatment in this setting.In this international, randomised, double-blind, double-dummy, phase 3 trial, we recruited patients aged 16 years or older with severe influenza admitted to 97 hospitals from 26 countries. We randomly assigned patients (1:1:1 stratified by symptom onset ≤4 days or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg oral oseltamivir) twice a day for 5-10 days; patients were followed up for 28 days. The randomisation schedule, including stratification, was generated using GlaxoSmithKline's RandAll software. Patients, site study staff, and sponsor were masked to study treatment. The primary endpoint was time to clinical response-a composite of vital sign stabilisation and hospital discharge-in the influenza-positive population. The trial was powered to show an improvement of 1·5 days or greater with 600 mg intravenous zanamivir. Pharmacokinetic, safety, and virology endpoints were also assessed. This trial is registered with ClinicalTrials.gov, number NCT01231620.Between Jan 15, 2011, and Feb 12, 2015, 626 patients were randomly assigned to receive 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir (n=205) twice a day; 11 patients discontinued the study before receiving any study treatment. 488 (78%) of 626 patients had laboratory-confirmed influenza. Compared with a median time to clinical response of 5·14 days in the 600 mg intravenous zanamivir group, the median time to clinical response was 5·87 days (difference of -0·73 days, 95% CI -1·79 to 0·75; p=0·25) in the 300 mg intravenous zanamivir group and 5·63 days (difference of -0·48 days, 95% CI -2·11 to 0·97; p=0·39) in the oseltamivir group. Four patients with influenza A/H1N1pdm09 in the oseltamivir group developed H275Y resistance mutations. Adverse events were reported in 373 (61%) of treated patients and were similar across treatment groups; the most common adverse events (300 mg intravenous zanamivir, 600 mg intravenous zanamivir, oseltamivir) were diarrhoea (10 [5%], 15 [7%], 14 [7%]), respiratory failure (11 [5%], 14 [7%], 11 [5%]), and constipation (7 [3%], 13 [6%], 10 [5%]). 41 (7%) treated patients died during the study (15 [7%], 15 [7%], 11 [5%]); the most common causes of death were respiratory failure and septic shock.Time to clinical response to intravenous zanamivir dosed at 600 mg was not superior to oseltamivir or 300 mg intravenous zanamivir. All treatments had a similar safety profile in hospitalised patients with severe influenza.GlaxoSmithKline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Akim的应助被王尹采纳,获得10
刚刚
1秒前
海鹏完成签到,获得积分10
1秒前
1秒前
dudududa完成签到,获得积分10
1秒前
文龙发布了新的文献求助10
1秒前
daidai完成签到,获得积分10
1秒前
nidahao完成签到 ,获得积分10
1秒前
小巧如音发布了新的文献求助10
1秒前
2秒前
初蓝完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
3秒前
76542cu发布了新的文献求助10
3秒前
3秒前
4秒前
HMLM完成签到,获得积分10
4秒前
4秒前
小泉完成签到,获得积分20
4秒前
4秒前
山河西瓜完成签到,获得积分10
5秒前
newfat发布了新的文献求助10
5秒前
5秒前
chao完成签到,获得积分20
5秒前
Jun给祖努尔的求助进行了留言
5秒前
王尹完成签到,获得积分20
6秒前
余香的应助被帅子采纳,获得10
6秒前
落后的道之完成签到,获得积分10
7秒前
柠溪发布了新的文献求助10
7秒前
搜集达人的应助被weeadas采纳,获得10
7秒前
7秒前
早日退休完成签到,获得积分10
7秒前
悦耳小夏发布了新的文献求助10
8秒前
8秒前
失眠的早晨完成签到,获得积分10
8秒前
liu的应助被whale采纳,获得10
8秒前
HLJ发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154737
求助须知:如何正确求助?哪些是违规求助? 9551274
关于积分的说明 21703821
捐赠科研通 7744087
什么是DOI,文献DOI怎么找? 3425933
关于科研通互助平台的介绍 2551048
邀请新用户注册赠送积分活动 2469643